In this online activity, Srdan Verstovsek, MD, PhD, explores predictive and prognostic markers for personalized care planning in myelofibrosis as well as emerging data in therapeutic strategies and the implications that research advances may have for future practice.

In this online activity, Judd Moul, MD, Duke University School of Medicine, reviews emerging data on novel therapies for metastatic castration-sensitive, metastatic castration-resistant, and nonmetastatic castration-resistant disease. Case challenges are used to illustrate strategies for optimizing treatment in the context of confounding patient and tumor variables. Start now!

Our third Oncology Data Advisor™ episode talks to Gilles Salles, MD, PhD, about efficacy of newly developed therapies, adverse events associated with these treatments, ongoing research, and advice for clinicians seeking to optimize outcomes for patients with MCL.

In this online activity, Jaffer Ajani, MD, MD Anderson Cancer Center, will review emerging data on novel therapies for patients with metastatic disease, including TKIs, monoclonal antibodies, immune checkpoint inhibitors, and cytotoxic therapy. Case challenges will be used to illustrate strategies for optimizing treatment in the context of confounding patient and tumor variables. Start the activity!

In this virtual tumor board, David P. Steensma, MD, FACP, Reza Nejati, MD, and Ilene Galinsky, BSN, MSN, ANP-C, discuss patient and tumor characteristics that inform personalized care plans, risk stratification, and supportive care strategies for patients with MDS.

The second episode of Oncology Data Advisor with Dr. Benson considers recent developments in genomic testings and targeted therapies, supportive care measures that can optimize quality of life, and strategies that can be utilized to improve outcomes of patients with pancreatic cancer.

Learn more about personalized care plans in advanced NSCLC with Mark A. Socinski, MD, Maureen F. Zakowski, MD and Victoria Sherry, DNP, CRNP, AOCNP^® as they discuss prognostic markers, current therapies, and adverse event management in this multidisciplinary virtual tumor board.

This case-based presentation developed by Arjun V. Balar, MD, discusses patient and tumor-related factors that can inform personalized care plans as well as novel therapies and adverse event management. Click to learn more and start the activity!

In this multidisciplinary discussion, James B. Bussel, MD & Allison Miller Imahiyerobo, APN explore ITP pathogenesis, current and emerging therapies, and supportive care strategies that help ITP patients achieve their goals of therapy. Register/Sign in to get started!

This episode of Oncology Data Advisor features Dr. Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, in a discussion that covers the changing treatment landscape, adverse events of concern with novel therapies, and advice for members of the cancer care team as they seek to optimize outcomes for patients with GIST.